Autopsy report · NCT04427072

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

“Company decision not related to any safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Capmatinib; Docetaxel

Participants

22

Sites

43

Countries

Belgium, Brazil, Bulgaria, France, Germany, Hungary, India, Italy, Lithuania, Malaysia, Netherlands, Portugal and more

Trials that died the same way

• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (80% match in meaning)
• A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
  “This was a strategic business decision. There were no safety concerns contributing to this decision.” (80% match in meaning)
• Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
  “Sponsor decision, the decision is not related to any safety concern.” (79% match in meaning)
• MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
  “Business Decision; No Safety Or Efficacy Concerns.” (77% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.